A citation-based method for searching scientific literature

Alexandre V Hirayama, Jordan Gauthier, Kevin A Hay, Jenna M Voutsinas, Qian Wu, Ted Gooley, Daniel Li, Sindhu Cherian, Xueyan Chen, Barbara S Pender, Reed M Hawkins, Aesha Vakil, Rachel N Steinmetz, Utkarsh H Acharya, Ryan D Cassaday, Aude G Chapuis, Tejaswini M Dhawale, Paul C Hendrie, Hans-Peter Kiem, Ryan C Lynch, Jorge Ramos, Mazyar Shadman, Brian G Till, Stanley R Riddell, David G Maloney, Cameron J Turtle. Blood 2019
Times Cited: 129







List of co-cited articles
826 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
68

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
64

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
52

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
807
50

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Jae H Park, Isabelle Rivière, Mithat Gonen, Xiuyan Wang, Brigitte Sénéchal, Kevin J Curran, Craig Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead,[...]. N Engl J Med 2018
42

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins, Colette Chaney, Sindhu Cherian, Xueyan Chen,[...]. Sci Transl Med 2016
601
39

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Theodore A Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine Melville, Barbara Pender, Tanya M Budiarto,[...]. J Clin Invest 2016
39

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, Armin Ghobadi, Cameron J Turtle, Jennifer N Brudno, Marcela V Maus, Jae H Park, Elena Mead, Steven Pavletic,[...]. Biol Blood Marrow Transplant 2019
831
37

Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, Pamela A Shaw, Richard Aplenc, David M Barrett, Nancy J Bunin, Anne Chew, Vanessa E Gonzalez, Zhaohui Zheng, Simon F Lacey,[...]. N Engl J Med 2014
30

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Joseph A Fraietta, Simon F Lacey, Elena J Orlando, Iulian Pruteanu-Malinici, Mercy Gohil, Stefan Lundh, Alina C Boesteanu, Yan Wang, Roddy S O'Connor, Wei-Ting Hwang,[...]. Nat Med 2018
635
30

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Stephen J Schuster, Jakub Svoboda, Elise A Chong, Sunita D Nasta, Anthony R Mato, Özlem Anak, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel Landsburg,[...]. N Engl J Med 2017
903
29

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
391
28

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, Juliane Gust, W Conrad Liles, Mark M Wurfel, José A López, Junmei Chen, Dominic Chung, Susanna Harju-Baker,[...]. Blood 2017
494
26

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry, Rimas Orentas, Marianna Sabatino, Nirali N Shah,[...]. Lancet 2015
26

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Cristina Gutierrez, Frederick L Locke, Krishna V Komanduri, Yi Lin, Nitin Jain, Naval Daver,[...]. Nat Rev Clin Oncol 2018
26

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Juliane Gust, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson, Luis F Gonzalez-Cuyar, Cecilia Yeung, W Conrad Liles, Mark Wurfel, Jose A Lopez,[...]. Cancer Discov 2017
616
25

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Kevin A Hay, Jordan Gauthier, Alexandre V Hirayama, Jenna M Voutsinas, Qian Wu, Daniel Li, Ted A Gooley, Sindhu Cherian, Xueyan Chen, Barbara S Pender,[...]. Blood 2019
150
25

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
James N Kochenderfer, Robert P T Somerville, Tangying Lu, Victoria Shi, Adrian Bot, John Rossi, Allen Xue, Stephanie L Goff, James C Yang, Richard M Sherry,[...]. J Clin Oncol 2017
313
25

Current concepts in the diagnosis and management of cytokine release syndrome.
Daniel W Lee, Rebecca Gardner, David L Porter, Chrystal U Louis, Nabil Ahmed, Michael Jensen, Stephan A Grupp, Crystal L Mackall. Blood 2014
24

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
David L Porter, Wei-Ting Hwang, Noelle V Frey, Simon F Lacey, Pamela A Shaw, Alison W Loren, Adam Bagg, Katherine T Marcucci, Angela Shen, Vanessa Gonzalez,[...]. Sci Transl Med 2015
23

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
649
23

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
Rebecca A Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen S Kelly-Spratt,[...]. Blood 2017
541
23

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn,[...]. N Engl J Med 2020
447
22

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
Margherita Norelli, Barbara Camisa, Giulia Barbiera, Laura Falcone, Ayurzana Purevdorj, Marco Genua, Francesca Sanvito, Maurilio Ponzoni, Claudio Doglioni, Patrizia Cristofori,[...]. Nat Med 2018
604
21

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Loretta J Nastoupil, Michael D Jain, Lei Feng, Jay Y Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan,[...]. J Clin Oncol 2020
195
21

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Bianca D Santomasso, Jae H Park, Darin Salloum, Isabelle Riviere, Jessica Flynn, Elena Mead, Elizabeth Halton, Xiuyan Wang, Brigitte Senechal, Terence Purdon,[...]. Cancer Discov 2018
350
20

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J Fry, Nirali N Shah, Rimas J Orentas, Maryalice Stetler-Stevenson, Constance M Yuan, Sneha Ramakrishna, Pamela Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates,[...]. Nat Med 2018
660
20

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
Luca Gattinoni, Steven E Finkelstein, Christopher A Klebanoff, Paul A Antony, Douglas C Palmer, Paul J Spiess, Leroy N Hwang, Zhiya Yu, Claudia Wrzesinski, David M Heimann,[...]. J Exp Med 2005
724
18

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
Theodoros Giavridis, Sjoukje J C van der Stegen, Justin Eyquem, Mohamad Hamieh, Alessandra Piersigilli, Michel Sadelain. Nat Med 2018
518
17

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
646
16

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska,[...]. Sci Transl Med 2014
16

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.
John Rossi, Patrick Paczkowski, Yueh-Wei Shen, Kevin Morse, Brianna Flynn, Alaina Kaiser, Colin Ng, Kyle Gallatin, Tom Cain, Rong Fan,[...]. Blood 2018
128
16

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Cameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, Sindhu Cherian, Xueyan Chen, Brent Wood, Arletta Lozanski, John C Byrd, Shelly Heimfeld,[...]. J Clin Oncol 2017
383
15

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
David T Teachey, Simon F Lacey, Pamela A Shaw, J Joseph Melenhorst, Shannon L Maude, Noelle Frey, Edward Pequignot, Vanessa E Gonzalez, Fang Chen, Jeffrey Finklestein,[...]. Cancer Discov 2016
552
15

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
Caron A Jacobson, Bradley D Hunter, Robert Redd, Scott J Rodig, Pei-Hsuan Chen, Kyle Wright, Mikel Lipschitz, Jerome Ritz, Yusuke Kamihara, Philippe Armand,[...]. J Clin Oncol 2020
92
16

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Joshua A Hill, Daniel Li, Kevin A Hay, Margaret L Green, Sindhu Cherian, Xueyan Chen, Stanley R Riddell, David G Maloney, Michael Boeckh, Cameron J Turtle. Blood 2018
214
14

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.
D Sommermeyer, M Hudecek, P L Kosasih, T Gogishvili, D G Maloney, C J Turtle, S R Riddell. Leukemia 2016
433
13

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Ana Cordeiro, Evandro D Bezerra, Alexandre V Hirayama, Joshua A Hill, Qian V Wu, Jenna Voutsinas, Mohamed L Sorror, Cameron J Turtle, David G Maloney, Merav Bar. Biol Blood Marrow Transplant 2020
95
13

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
James N Kochenderfer, Mark E Dudley, Steven A Feldman, Wyndham H Wilson, David E Spaner, Irina Maric, Maryalice Stetler-Stevenson, Giao Q Phan, Marybeth S Hughes, Richard M Sherry,[...]. Blood 2012
13

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson,[...]. J Clin Invest 2019
304
13

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei,[...]. J Hematol Oncol 2018
241
13

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Enli Liu, David Marin, Pinaki Banerjee, Homer A Macapinlac, Philip Thompson, Rafet Basar, Lucila Nassif Kerbauy, Bethany Overman, Peter Thall, Mecit Kaplan,[...]. N Engl J Med 2020
630
13

Chimeric Antigen Receptor Therapy.
Carl H June, Michel Sadelain. N Engl J Med 2018
822
13

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A Grupp, Michael Kalos, David Barrett, Richard Aplenc, David L Porter, Susan R Rheingold, David T Teachey, Anne Chew, Bernd Hauck, J Fraser Wright,[...]. N Engl J Med 2013
13

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
James N Kochenderfer, Mark E Dudley, Sadik H Kassim, Robert P T Somerville, Robert O Carpenter, Maryalice Stetler-Stevenson, James C Yang, Giao Q Phan, Marybeth S Hughes, Richard M Sherry,[...]. J Clin Oncol 2015
13

Mechanisms of resistance to CAR T cell therapy.
Nirali N Shah, Terry J Fry. Nat Rev Clin Oncol 2019
322
12

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Elena J Orlando, Xia Han, Catherine Tribouley, Patricia A Wood, Rebecca J Leary, Markus Riester, John E Levine, Muna Qayed, Stephan A Grupp, Michael Boyer,[...]. Nat Med 2018
228
12

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
James N Kochenderfer, Wyndham H Wilson, John E Janik, Mark E Dudley, Maryalice Stetler-Stevenson, Steven A Feldman, Irina Maric, Mark Raffeld, Debbie-Ann N Nathan, Brock J Lanier,[...]. Blood 2010
865
12

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
Kevin J Curran, Steven P Margossian, Nancy A Kernan, Lewis B Silverman, David A Williams, Neerav Shukla, Rachel Kobos, Christopher J Forlenza, Peter Steinherz, Susan Prockop,[...]. Blood 2019
90
13

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Justin Eyquem, Jorge Mansilla-Soto, Theodoros Giavridis, Sjoukje J C van der Stegen, Mohamad Hamieh, Kristen M Cunanan, Ashlesha Odak, Mithat Gönen, Michel Sadelain. Nature 2017
803
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.